1.Prediction of Early Recanalization after Intravenous Thrombolysis in Patients with Large-Vessel Occlusion
Young Dae KIM ; Hyo Suk NAM ; Joonsang YOO ; Hyungjong PARK ; Sung-Il SOHN ; Jeong-Ho HONG ; Byung Moon KIM ; Dong Joon KIM ; Oh Young BANG ; Woo-Keun SEO ; Jong-Won CHUNG ; Kyung-Yul LEE ; Yo Han JUNG ; Hye Sun LEE ; Seong Hwan AHN ; Dong Hoon SHIN ; Hye-Yeon CHOI ; Han-Jin CHO ; Jang-Hyun BAEK ; Gyu Sik KIM ; Kwon-Duk SEO ; Seo Hyun KIM ; Tae-Jin SONG ; Jinkwon KIM ; Sang Won HAN ; Joong Hyun PARK ; Sung Ik LEE ; JoonNyung HEO ; Jin Kyo CHOI ; Ji Hoe HEO ;
Journal of Stroke 2021;23(2):244-252
Background:
and Purpose We aimed to develop a model predicting early recanalization after intravenous tissue plasminogen activator (t-PA) treatment in large-vessel occlusion.
Methods:
Using data from two different multicenter prospective cohorts, we determined the factors associated with early recanalization immediately after t-PA in stroke patients with large-vessel occlusion, and developed and validated a prediction model for early recanalization. Clot volume was semiautomatically measured on thin-section computed tomography using software, and the degree of collaterals was determined using the Tan score. Follow-up angiographic studies were performed immediately after t-PA treatment to assess early recanalization.
Results:
Early recanalization, assessed 61.0±44.7 minutes after t-PA bolus, was achieved in 15.5% (15/97) in the derivation cohort and in 10.5% (8/76) in the validation cohort. Clot volume (odds ratio [OR], 0.979; 95% confidence interval [CI], 0.961 to 0.997; P=0.020) and good collaterals (OR, 6.129; 95% CI, 1.592 to 23.594; P=0.008) were significant factors associated with early recanalization. The area under the curve (AUC) of the model including clot volume was 0.819 (95% CI, 0.720 to 0.917) and 0.842 (95% CI, 0.746 to 0.938) in the derivation and validation cohorts, respectively. The AUC improved when good collaterals were added (derivation cohort: AUC, 0.876; 95% CI, 0.802 to 0.950; P=0.164; validation cohort: AUC, 0.949; 95% CI, 0.886 to 1.000; P=0.036). The integrated discrimination improvement also showed significantly improved prediction (0.097; 95% CI, 0.009 to 0.185; P=0.032).
Conclusions
The model using clot volume and collaterals predicted early recanalization after intravenous t-PA and had a high performance. This model may aid in determining the recanalization treatment strategy in stroke patients with large-vessel occlusion.
2.Prediction of Early Recanalization after Intravenous Thrombolysis in Patients with Large-Vessel Occlusion
Young Dae KIM ; Hyo Suk NAM ; Joonsang YOO ; Hyungjong PARK ; Sung-Il SOHN ; Jeong-Ho HONG ; Byung Moon KIM ; Dong Joon KIM ; Oh Young BANG ; Woo-Keun SEO ; Jong-Won CHUNG ; Kyung-Yul LEE ; Yo Han JUNG ; Hye Sun LEE ; Seong Hwan AHN ; Dong Hoon SHIN ; Hye-Yeon CHOI ; Han-Jin CHO ; Jang-Hyun BAEK ; Gyu Sik KIM ; Kwon-Duk SEO ; Seo Hyun KIM ; Tae-Jin SONG ; Jinkwon KIM ; Sang Won HAN ; Joong Hyun PARK ; Sung Ik LEE ; JoonNyung HEO ; Jin Kyo CHOI ; Ji Hoe HEO ;
Journal of Stroke 2021;23(2):244-252
Background:
and Purpose We aimed to develop a model predicting early recanalization after intravenous tissue plasminogen activator (t-PA) treatment in large-vessel occlusion.
Methods:
Using data from two different multicenter prospective cohorts, we determined the factors associated with early recanalization immediately after t-PA in stroke patients with large-vessel occlusion, and developed and validated a prediction model for early recanalization. Clot volume was semiautomatically measured on thin-section computed tomography using software, and the degree of collaterals was determined using the Tan score. Follow-up angiographic studies were performed immediately after t-PA treatment to assess early recanalization.
Results:
Early recanalization, assessed 61.0±44.7 minutes after t-PA bolus, was achieved in 15.5% (15/97) in the derivation cohort and in 10.5% (8/76) in the validation cohort. Clot volume (odds ratio [OR], 0.979; 95% confidence interval [CI], 0.961 to 0.997; P=0.020) and good collaterals (OR, 6.129; 95% CI, 1.592 to 23.594; P=0.008) were significant factors associated with early recanalization. The area under the curve (AUC) of the model including clot volume was 0.819 (95% CI, 0.720 to 0.917) and 0.842 (95% CI, 0.746 to 0.938) in the derivation and validation cohorts, respectively. The AUC improved when good collaterals were added (derivation cohort: AUC, 0.876; 95% CI, 0.802 to 0.950; P=0.164; validation cohort: AUC, 0.949; 95% CI, 0.886 to 1.000; P=0.036). The integrated discrimination improvement also showed significantly improved prediction (0.097; 95% CI, 0.009 to 0.185; P=0.032).
Conclusions
The model using clot volume and collaterals predicted early recanalization after intravenous t-PA and had a high performance. This model may aid in determining the recanalization treatment strategy in stroke patients with large-vessel occlusion.
3.Guidelines for Non-variceal Upper Gastrointestinal Bleeding
Joon Sung KIM ; Byung-Wook KIM ; Do Hoon KIM ; Chan Hyuk PARK ; Hyuk LEE ; Moon Kyung JOO ; Da Hyun JUNG ; Jun-Won CHUNG ; Hyuk Soon CHOI ; Gwang Ho BAIK ; Jeong Hoon LEE ; Kyo Young SONG ; Saebeom HUR ; ; ; ;
The Korean Journal of Gastroenterology 2020;75(6):322-332
Non-variceal upper gastrointestinal bleeding (NVUGIB) refers to bleeding that develops in the gastrointestinal tract proximal to the ligament of Treitz. NVUGIB is an important cause for visiting the hospital and is associated with significant morbidity and mortality. Although European and Asian-Pacific guidelines have been published, there has been no previous guidelines regarding management of NVUGIB in Korea. Korea is a country with a high prevalence of Helicobacter pylori infection and patients have easy accessibility to receive endoscopy. Therefore, we believe that guidelines regarding management of NVUGIB are mandatory. The Korean Society of Gastroenterology reviewed recent evidence and recommends practical management guidelines on NVUGIB in Korea.
4.The pattern of postoperative quality of life following minimally invasive gastrectomy for gastric cancer: a prospective cohort from Korean multicenter robotic gastrectomy trial
Jong-Ho CHOI ; Sang-Uk HAN ; Han-Kwang YANG ; Young-Woo KIM ; Keun Won RYU ; Joong-Min PARK ; Ji Yeong AN ; Min-Chan KIM ; Sungsoo PARK ; Kyo Young SONG ; Sung Jin OH ; Seong-Ho KONG ; Byoung Jo SUH ; Dae Hyun YANG ; Tae Kyung HA ; Hyoung-Il KIM ; Woo Jin HYUNG ; Hyuk-Joon LEE
Annals of Surgical Treatment and Research 2020;99(5):275-284
Purpose:
Quality of life (QOL) has become important in the trend of emphasizing patient satisfaction. This study aimed to evaluate the QOL in patients who underwent laparoscopic or robotic gastrectomy for gastric cancer.
Methods:
A prospective trial was performed involving patients who underwent laparoscopic or robotic gastrectomy for primary gastric cancer at 11 hospitals in Korea. Within this comparative trial, QOL, postoperative pain, and long-term complications were exanimated. The quality-of-life questionnaire (QLQ)-C30 and QLQ-STO22 developed by the European Organization for Research and Treatment of Cancer were used for the QOL survey. We compared the data after dividing it into several types of characteristics as follows; device (robotic or laparoscopic), operation type, pathological stage, and sex.Biased components were extracted by logistic regression analysis. Propensity score matching was applied to the data set with the biased components.
Results:
In total, 434 patients (211 for laparoscopic surgery and 223 for robotic surgery) were enrolled, out of which 321 patients who responded to both preoperative and postoperative surveys were selected for analysis. Robotic gastrectomy was not different from laparoscopic gastrectomy with respect to postoperative QOL. Distal gastrectomy showed better scores than total gastrectomy in terms of role functioning, social functioning, fatigue, nausea/vomiting, pain, dyspnea, constipation, financial difficulties, dysphagia, eating restrictions, anxiety, taste, and body image. Male patients showed better scores on the 19 scales compared to female patients.
Conclusion
Robotic and laparoscopic approaches for gastric cancer surgery did not differ from each other with respect to QOL. Distal gastrectomy resulted in better QOL than total gastrectomy.
5.Guidelines for Nonvariceal Upper Gastrointestinal Bleeding
Joon Sung KIM ; Byung-Wook KIM ; Do Hoon KIM ; Chan Hyuk PARK ; Hyuk LEE ; Moon Kyung JOO ; Da Hyun JUNG ; JunWon CHUNG ; Hyuk Soon CHOI ; Gwang Ho BAIK ; Jeong Hoon LEE ; Kyo Young SONG ; Saebeom HUR
Gut and Liver 2020;14(5):560-570
Nonvariceal upper gastrointestinal bleeding (NVUGIB) refers to bleeding that develops in the gastrointestinal tract proximal to the ligament of Treitz. NVUGIB requires hospitalization and is associated with significant morbidity and mortality.Although European and Asian-Pacific guidelines have been published, there have been no previous guidelines regarding management of NVUGIB in Korea. Korea has a high prevalence of Helicobacter pylori infections, and patients have easy accessibility to endoscopy. Therefore, we believe that guidelines regarding management of NVUGIB in Korea are essential. The Korean Society of Gastroenterology reviewed the recent evidence and recommends practical management guidelines on NVUGIB in Korea.
6.Vagolytic atropine attenuates cerebral vasodilation response during acute orthostatic hypotension.
Woo Jong CHOI ; Kichang LEE ; Young Kug KIM ; Kyo Joon SONG ; Sung Moon JEONG ; Gyu Sam HWANG
Korean Journal of Anesthesiology 2015;68(6):594-602
BACKGROUND: Atropine is an anticholinergic drug which is commonly used in clinical practice. The effect of parasympathetic block with atropine on dynamic cerebrovascular regulation remains unclear. This study was aimed to identify effects of vagolytic atropine on cerebrovascular response during acute orthostatic hypotension in humans. METHODS: Continuous middle cerebral blood flow velocity (CBFV, transcranial Doppler) and arterial blood pressure (ABP, Finometer) were measured during a sit-to-stand procedure in 10 healthy subjects with placebo and vagolytic (10 microg/kg) doses of atropine. Cerebral vascular tone was assessed by cerebrovascular resistance (CVR = ABP / CBFV). Dynamic cerebral autoregulation was also assessed by transfer function analysis of ABP and CBFV. RESULTS: During the standing session, ABP fell to a similar extent in both groups by an average of 23 to 25 mmHg (26% to 29%). CBFV also fell in all subjects but significantly more in vagolytic atropine (-15.0 +/- 7.0 cm/s) compared with placebo (-12.0 +/- 5.8 cm/s, P < 0.05). CVR was decreased significantly in the placebo group during posture change (1.56 +/- 0.44 vs. 1.38 +/- 0.38, P < 0.05), in contrast, lesser decreased in the atropine group (1.60 +/- 0.50 vs. 1.53 +/- 0.42, P = 0.193). Transfer function coherence in the very-low-frequency range was significantly increased in the atropine group during the standing session (0.55 +/- 0.14), compared with the sitting session (0.45 +/- 0.14, P = 0.006). CONCLUSIONS: These data present that vagolytic atropine attenuates cerebral vasodilation response to acute orthostatic hypotension, suggesting the use of atropine may need care in patients with cerebrovascular disease with vagal impairment.
Arterial Pressure
;
Atropine*
;
Blood Flow Velocity
;
Homeostasis
;
Humans
;
Hypotension, Orthostatic*
;
Posture
;
Vasodilation*
7.A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy.
Hee Yeon LEE ; Hoon Kyo KIM ; Kyung Hee LEE ; Bong Seog KIM ; Hong Suk SONG ; Sung Hyun YANG ; Joon Hee KIM ; Yeul Hong KIM ; Jong Gwang KIM ; Sang We KIM ; Dong Wan KIM ; Si Young KIM ; Hee Sook PARK
Cancer Research and Treatment 2014;46(1):19-26
PURPOSE: This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting. MATERIALS AND METHODS: This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6. RESULTS: Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events. CONCLUSION: In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.
Antineoplastic Agents
;
Constipation
;
Dexamethasone
;
Drug Therapy*
;
Hiccup
;
Humans
;
Incidence
;
Korea
;
Nausea*
;
Ondansetron*
;
Prospective Studies
;
Serotonin Antagonists
;
Vomiting*
8.ERRATUM: Correction for the number of the recruited patients and the participating institutions. Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrectomy with open distal gastrectomy for gastric adenocarcinoma (KLAS.
Hyung Ho KIM ; Sang Uk HAN ; Min Chan KIM ; Woo Jin HYUNG ; Wook KIM ; Hyuk Joon LEE ; Seung Wan RYU ; GyuSeok CHO ; Chan Young KIM ; Han Kwang YANG ; Do Joong PARK ; Kyo Young SONG ; Sang Il LEE ; Seong Yeob RYU ; Joo Ho LEE
Annals of Surgical Treatment and Research 2014;87(1):51-52
We found an Fig. 1 error in our published article.
9.Prospective randomized controlled trial (phase III) to comparing laparoscopic distal gastrectomy with open distal gastrectomy for gastric adenocarcinoma (KLASS 01).
Hyung Ho KIM ; Sang Uk HAN ; Min Chan KIM ; Woo Jin HYUNG ; Wook KIM ; Hyuk Joon LEE ; Seung Wan RYU ; Gyu Seok CHO ; Chan Young KIM ; Han Kwang YANG ; Do Joong PARK ; Kyo Young SONG ; Sang Il LEE ; Seong Yeob RYU ; Joo Ho LEE
Journal of the Korean Surgical Society 2013;84(2):123-130
A randomized controlled trial to evaluate the long-term outcomes of laparoscopic distal gastrectomy for gastric cancer is currently ongoing in Korea. Patients with cT1N0M0-cT2aN0M0 (American Joint Committee on Cancer, 6th edition) distal gastric cancer were randomized to receive either laparoscopic or open distal gastrectomy. For surgical quality control, the surgeons participating in this trial had to have performed at least 50 cases each of laparoscopy-assisted distal gastrectomy and open distal gastrectomy and their institutions should have performed more than 80 cases each of both procedures each year. Fifteen surgeons from 12 institutions recruited 1,415 patients. The primary endpoint is overall survival. The secondary endpoints are disease-free survival, morbidity, mortality, quality of life, inflammatory and immune responses, and cost-effectiveness (ClinicalTrials.gov ID: NCT00452751).
Adenocarcinoma
;
Disease-Free Survival
;
Gastrectomy
;
Humans
;
Joints
;
Korea
;
Prospective Studies
;
Quality Control
;
Quality of Life
;
Stomach Neoplasms
10.Clinical Outcomes according to Primary Treatment in Gastric Cancer Patients with Peritoneal Seeding.
Jung Min BAE ; Kyoung Joon YEO ; Se Won KIM ; Sang Woon KIM ; Sun Kyo SONG
Journal of Gastric Cancer 2011;11(3):167-172
PURPOSE: Peritoneal seeding of gastric cancer is known to have a poor prognosis. With the diagnosis of peritoneal seeding, there is no effective treatment modality. Gastrectomy with chemotherapy or primary chemotherapy is basically one of major options for this condition. This study was conducted to compare the clinical outcomes of these treatments and to identify the better way to improve the prognosis of patients with peritoneal seeding. MATERIALS AND METHODS: Between 2001 and 2007, gastric cancer patients with peritoneal seeding by preoperative or intraoperative diagnosis were reviewed retrospectively. The enrolled patients were divided as primary gastrectomy and primary chemotherapy group. Clinicopathologic characteristics and clinical outcomes of groups were analyzed and compared. RESULTS: Fifty-four patients were enrolled. 21 patients belonged to the group of primary gastrectomy and 33 patients were to the primary chemotherapy group. Among 33 patients of the primary chemotherapy group, 17 patients were received only chemotherapy and 16 patients were received gastrectomy due to the good responses of primary chemotherapy. The 3 years survival rates were 14% in primary gastrectomy group, 55% in patients who received gastrectomy after primary chemotherapy, and 0% in patients with primary chemotherapy only. CONCLUSIONS: Although this study had many limitations, some valuable information was produced. In terms of survival benefits for the gastric cancer patients with peritoneal seeding, primary gastrectomy and additional gastrectomy after primary chemotherapy revealed the better clinical outcomes. But, prospective randomized clinical study and multi-center study are should be performed to decide proper treatment for gastric cancer patients with peritoneal seeding.
Gastrectomy
;
Humans
;
Prognosis
;
Retrospective Studies
;
Seeds
;
Stomach Neoplasms
;
Survival Rate

Result Analysis
Print
Save
E-mail